Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
100 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05201781 | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | recruiting | Phase 4 | 295 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) |
| recruiting |
| Phase 4 |
| 50 |
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY |
| 6 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT03048084 | Seizure Treatment in Glioma(STING) | recruiting | Phase 4 | 120 | Leiden University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06908070 | Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab(CROWD) | recruiting | Phase 4 | 38 | Idris BahceOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07645625 | Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer(PROTECx) | recruiting | Phase 4 | 261 | University Medical Center GroningenOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT06031233 | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie(MINUTE) | recruiting | Phase 4 | 776 | IsalaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06748001 | Avapritinib Rollover Study | recruiting | Phase 4 | 60 | Blueprint Medicines CorporationINDUSTRY | 6 | Feb 9, 2026 | clinicaltrials |
| NCT07262957 | Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)(PANENCA) | recruiting | Phase 4 | 400 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06717919 | HOPE Against Cancer Recurrence in HCC(HOPE4Cancer) | recruiting | Phase 4 | 220 | Philipp DutkowskiOTHER | 17 | Dec 16, 2025 | clinicaltrials |
| NCT01496313 | To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer | completed | Phase 4 | 81 | SanofiINDUSTRY | 9 | Oct 3, 2025 | clinicaltrials |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer(EXAMINER) | active not recruiting | Phase 4 | 247 | ExelixisINDUSTRY | 14 | Sep 2, 2025 | clinicaltrials |
| NCT07001709 | Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)(ENABLE) | recruiting | Phase 4 | 29 | Deventer ZiekenhuisOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06499415 | Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis(CALM) | recruiting | Phase 4 | 232 | Maastricht University Medical CenterOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03909646 | Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease(BOWTIE) | completed | Phase 4 | 250 | Maastricht University Medical CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05555329 | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study(POMAlternative) | completed | Phase 4 | 12 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06875258 | PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)(PEHAB-II) | recruiting | Phase 4 | 198 | The Netherlands Cancer InstituteOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05463913 | Lung Nodule Detection Using Ultra-long FOV PET/CT | recruiting | Phase 4 | 20 | University Medical Center GroningenOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04524442 | Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | completed | Phase 4 | 42 | Advanced Accelerator ApplicationsINDUSTRY | 4 | Jan 24, 2025 | clinicaltrials |
| NCT03285763 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)(TAIL) | completed | Phase 4 | 619 | Hoffmann-La RocheINDUSTRY | 24 | Jan 23, 2025 | clinicaltrials |
| NCT06785974 | Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis(SPIRAL) | not yet recruiting | Phase 4 | 140 | Erasmus Medical CenterOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT04646187 | De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease(FREE) | enrolling by invitation | Phase 4 | 148 | University Medical Center GroningenOTHER | 3 | Jan 6, 2025 | clinicaltrials |
| NCT04526704 | Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib(PLX3397) | completed | Phase 4 | 32 | Daiichi SankyoINDUSTRY | 7 | Dec 30, 2024 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05216328 | Prevention of Opioid-induced Constipation in Patients With Advanced Cancer(OMAMA) | recruiting | Phase 4 | 330 | Amsterdam UMC, location VUmcOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT05784311 | Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)(SPARROW) | recruiting | Phase 4 | 344 | Leiden University Medical CenterOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT06118710 | Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment(DEXASTOP) | recruiting | Phase 4 | 500 | Erasmus Medical CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT01379898 | Phenoxybenzamine Versus Doxazosin in PCC Patients(PRESCRIPT) | completed | Phase 4 | 134 | University Medical Center GroningenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05748093 | Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat(OSIBOOST 2) | unknown | Phase 4 | 60 | Maastricht University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06498037 | Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.(FERRARI) | unknown | Phase 4 | 45 | Erasmus Medical CenterOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT05701241 | Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients(SAUNA) | recruiting | Phase 4 | 270 | University Hospital, AntwerpOTHER | 2 | Jun 14, 2024 | clinicaltrials |
| NCT03927391 | Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects(REDOSE) | completed | Phase 4 | 57 | Radboud University Medical CenterOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05078671 | Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness(PROACTIVE) | unknown | Phase 4 | 160 | Radboud University Medical CenterOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC) | recruiting | Phase 4 | 196 | University Medical Center GroningenOTHER | 2 | May 13, 2024 | clinicaltrials |
| NCT06314763 | Rivaroxaban Sotorasib Interaction Study(ROSIE) | completed | Phase 4 | 21 | Radboud University Medical CenterOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06116461 | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response(NIVOPTIMIZE) | unknown | Phase 4 | 34 | Erasmus Medical CenterOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT01641172 | Taste, Smell and Chemotherapy (TASTY)(TASTY) | completed | Phase 4 | 140 | University Medical Center GroningenOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT00942968 | Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer | completed | Phase 4 | 338 | PfizerINDUSTRY | 5 | Apr 18, 2024 | clinicaltrials |
| NCT03817853 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 7 | Apr 4, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05525481 | Tamoxifen Prediction Study in Patients With ER+ Breast Cancer(PREDICTAM) | unknown | Phase 4 | 100 | Erasmus Medical CenterOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06010277 | Folinic Acid for Prevention of Pemetrexed-induced Toxicity(FLEX) | unknown | Phase 4 | 50 | Amphia HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT01957176 | A Rollover Study to Provide Continued Treatment With Eltrombopag | completed | Phase 4 | 22 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 30, 2022 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials